Wednesday, June 28, 2017

Further therapies

As our line of defenses in treatments fail, PCa advances into a new state of growth. This is generally known as advanced PCa. Advanced PCa is known to be in any one of these state:
Metastatic, asymptomatic, hormone-refractory prostate cancer.
Metastatic castrate-resistant (mCRPC).
Androgen-independent (AI) prostate cancer.
Our Oncologist will have to determine the state of our advanced PCa in order to prescribe the next line of defense. Drugs and protocols for advanced PCa are actively on-going. Immunotherapy leads in this area of treatment.
Cancer patients need to know that Radiotherapy can be done after Prostatectomy, but Prostatectomy cannot be done after Radiotherapy. How ever Hormone Therapy is the standard treatment protocol after either treatment fails.
The following FDA approved drugs may be prescribed in addition to hormone therapy:
Abiraterone (Zytiga) and prednisone.
Enzalutamide (Xtandi).
Radium-223 (Xofigo) for men with cancer that has spread to the bone.
Docetaxel (Docefrez, Taxotere) and prednisone.
Sipuleucel-T (Provenge) for men who have few or no symptoms from the cancer
Cabazitaxel (Jevtana) and prednisone for men with prostate cancer that has worsened while receiving docetaxel.
Mitoxantrone (Novantrone) plus prednisone.
Bicalutamide (Casodex), flutamide (Eulexin), nilutamide (Nilandron), which are all types of anti-androgens.
Ketoconazole (Nizoral, Xolegel).
Low-dose corticosteroids.

Take care

Allen Lai

No comments:

Post a Comment